By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Inspyr (Formerly Known As GenSpera) 

2511 N Loop 1604 W
Suite 204 (3rd Floor)
San Antonio  Texas  78258  U.S.A.
Phone: 210-479-8112 Fax: 210-479-8113


Inspyr Therapeutics is a biotechnology company focused on the development and commercialization of promising, new therapeutics. Our work is motivated by a commitment to innovation and helping patients. We combine our powerful insights and rigorous scientific methods to create new treatment options for patients.




CEO: Christopher Lowe

COO: Russell B. Richerson

CMO, SVP: Dr. Ronald L. Shazer

Interim Chairman: Peter E. Grebow


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Inspyr
Symbol: GNSZ


Company News
Inspyr (GNSZ) And Lewis And Clark Pharmaceuticals Complete Merger 9/13/2017 7:52:20 AM
Inspyr (GNSZ) Announces Private Placement Of Senior Convertible Debentures 9/12/2017 10:39:45 AM
Inspyr (GNSZ) And Lewis And Clark Pharmaceuticals To Merge 5/31/2017 11:02:02 AM
Inspyr (GNSZ) Appoints NIH Veterans To Lead New Translational Medicine Initiatives And Pipeline Expansion 3/6/2017 9:41:47 AM
Inspyr (GNSZ) Appoints Claire Thom, Pharm.D. To Board Of Directors 10/13/2016 10:09:19 AM
Inspyr (GNSZ) Appoints Richard Buller, M.D., Ph.D. To Board Of Directors 10/13/2016 10:02:52 AM
Inspyr (GNSZ) Announces The Initiation Of A Phase 2 Clinical Trial Of Mipsagargin For Newly Diagnosed Prostate Cancer Patients 8/17/2016 9:39:41 AM
With a New Name and CEO, Inspyr (GNSZ) Now Seeks a Partner for Cash to Fund Trial 8/10/2016 6:25:49 AM
GenSpera Announces Name Change To Inspyr Therapeutics 8/2/2016 9:22:59 AM
Biotech GenSpera's Future Uncertain as CEO and CFO Dionne Steps Down, Effective Immediately 3/23/2016 6:13:10 AM